Researchers reported that anisodine can block vasogenic cerebral edema in an ischemic stroke therapeutic context, targeting mechanisms tied to edema that can arise after delayed administration of rtPA. The work, attributed to Guo, Li, Chen, and colleagues, is scheduled for publication in Nature. The report frames anisodine as a potential modifier of a high-stakes complication in stroke management—vasogenic edema—aiming to preserve brain tissue during the period when edema pathways can worsen outcomes. The key point for translational development is the proposed molecular mechanism and the timing relevance relative to rtPA delivery. If confirmed in further preclinical and clinical evaluation, such an approach could become a combinable strategy to expand the therapeutic window for patients receiving or not receiving thrombolytics.